Welclop Tablet is a combination analgesic and anti-inflammatory medication containing Aceclofenac (100mg), Paracetamol (325mg), and Serratiopeptidase (15mg). Aceclofenac, a non-steroidal anti-inflammatory drug (NSAID), provides effective relief from pain and inflammation by inhibiting cyclooxygenase enzymes involved in prostaglandin synthesis. Paracetamol acts as an analgesic and antipyretic, offering additional pain relief and fever reduction through central inhibition of prostaglandin synthesis. Serratiopeptidase, a proteolytic enzyme, facilitates the breakdown of inflammatory mediators and promotes the resolution of swelling and edema. This combination is indicated for the management of acute and chronic musculoskeletal pain, osteoarthritis, rheumatoid arthritis, postoperative pain, and soft tissue inflammatory conditions. Welclop Tablet is particularly beneficial in reducing pain, inflammation, and associated discomfort, thereby improving patient mobility and quality of life. It should be used under medical supervision, with caution advised in patients with a history of gastrointestinal ulcers, bleeding disorders, or hepatic and renal impairment. Common adverse effects may include gastrointestinal disturbances, allergic reactions, or mild dizziness. Patients are advised to follow prescribed dosages and report any unusual symptoms promptly to their healthcare provider. Welclop Tablet offers a synergistic approach to pain management by combining anti-inflammatory, analgesic, and proteolytic actions in a single formulation.